Beeline Medicines has reported positive topline findings from a global phase 2 study of afimetoran in systemic lupus erythematosus (SLE), with the investigational therapy meeting its primary endpoint and supporting plans to advance the drug into pivotal development for both systemic and cutaneous forms of lupus.
Afimetoran is an investigational oral, once-daily small-molecule inhibitor of Toll-like receptors 7 and 8 (TLR7 and TLR8). The biotechnology company has identified the candidate as the lead asset in its pipeline following its emergence from stealth mode in April with $300 million in funding and five assets acquired from Bristol Myers Squibb (BMS). In June, the company added a $126 million series A extension to support pipeline development.
Phase 2 Trial Achieved Primary Endpoint at Week 48
The phase 2 study enrolled 248 adults between 18 and 70 years of age with active moderate-to-severe SLE despite ongoing treatment. Participants were randomly assigned in a 1:1:1:1 ratio to receive one of three afimetoran dose levels or placebo once daily for 48 weeks, alongside protocol-permitted standard-of-care medications, including corticosteroids with a mandatory taper.
According to Beeline, all three afimetoran dose groups recorded higher SLE Responder Index-4 (SRI-4) response rates at Week 48 compared with placebo. The company reported statistically significant improvements across all three dose groups, with p-values below 0.001.
The primary endpoint measured SRI-4 response at Week 48. Secondary assessments examined disease activity, low disease activity status, skin and joint manifestations, corticosteroid reduction, physician global assessment, and quality of life. Beeline said results from these secondary measures were consistent with the primary endpoint findings and supported the overall efficacy profile of the treatment.
Detailed findings from the study are expected to be presented at a future medical congress.
Safety Profile Aligned With Earlier Studies
The company stated that afimetoran’s safety and tolerability profile was generally consistent with observations from previous phase 1 clinical trials. No new safety signals were identified during the phase 2 study.
Before the asset was transferred to Beeline, BMS evaluated afimetoran in a first-in-human safety study and a phase 1b trial in cutaneous lupus erythematosus (CLE). Those studies showed a favorable safety profile. Afimetoran also demonstrated exploratory efficacy in a phase 1b CLE study and received Fast Track designation from the U.S. Food and Drug Administration for SLE in May 2025.
Plans to Advance Development in Two Forms of Lupus
Based on the phase 2 results, Beeline plans to move afimetoran into pivotal development for both SLE and CLE.
Saqib Islam, Chief Executive Officer of Beeline Medicines, said, “Too many people with systemic lupus continue to cycle through therapies that do not adequately control their disease, leaving them with diminished quality of life and vulnerable to debilitating long-term complications.”
Nathalie Franchimont, the company’s Chief Medical Officer, said there remains a need for therapies that are effective and well tolerated for people living with lupus. She said the phase 2 findings showed clinically meaningful effects across measures of disease activity and supported the company’s view that TLR7/8 inhibition may address both systemic and cutaneous manifestations of the disease.
TLR7 and TLR8 Continue to Draw Attention in Lupus Research
Interest in TLR7 and TLR8 as treatment targets has grown following research examining their role in lupus. Studies have implicated TLR7 in SLE, while later research identified TLR7 gain-of-function genetic variation as a cause of lupus. Other research groups have also investigated the role of TLR8 in the autoimmune disease.
Beeline’s development plans for afimetoran come as other companies pursue the same mechanism. Merck KGaA’s enpatoran, another oral TLR7/8 inhibitor, entered phase 3 development in SLE and CLE this year.
Beeline executives have previously indicated a preference for advancing assets independently. Islam recently said the team has experience taking medicines through regulatory review to approval and pricing and intends to do so again.
Beeline Medicines has announced positive topline results from its global Phase 2 study of afimetoran in adults with active moderate-to-severe systemic lupus erythematosus (SLE). The Beeline study met its primary endpoint, with all three afimetoran dose groups producing higher SRI-4 response rates than placebo at Week 48. Statistical significance was achieved across all three dose groups, with p-values below 0.001.
The results represent an important milestone for Beeline as the company prepares to move afimetoran into pivotal development for lupus.
Beeline Demonstrates Positive SRI-4 Results
The primary endpoint for the Beeline Phase 2 trial measured the proportion of patients achieving an SLE Responder Index-4 (SRI-4) response at Week 48. According to Beeline, each of the three afimetoran dose groups demonstrated a stronger response than the placebo group.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
